THERAPY DOSSIER · th-4127501769a9

Agar-based biopolymer spinal bridge scaffolds with linear empty channels, mixed with kappa-carrageenan, gelatin, xanthan gum or polysulfone

Device · Device (agar-based biopolymer spinal bridge scaffold); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Device (agar-based biopolymer spinal bridge scaffold); not a ChEMBL entity
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23988711 ↗2013Mixed findings

Agar-based bridges as biocompatible candidates to provide guide cues in spinal cord injury repair.

RatSpinal cord injuryComplete transectionWistarMaleSurgical implantation into the transection gapAt the time of transection (acute implantation)

Model: Acute complete spinal cord transection at thoracic level T8

All mixtures except agar plus gelatin were stable and porous and elicited a low host reaction with peripheral sensory (CGRP-positive) neurite ingrowth, but central axons did not cross into the bridges, collagen accumulated in the channels and channel linearity was lost.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…